# A Single Center Study to Characterize the Absorption, Distribution, Metabolism and Excretion (ADME) of ASA404 After a Single Infusion in Patients With Solid Tumors

> **NCT01299701** · PHASE1 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 7 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** ASA404

## Key facts

- **NCT ID:** NCT01299701
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-12
- **Primary completion:** 2009-07
- **Final completion:** 2009-07
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2017-02-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01299701

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01299701, "A Single Center Study to Characterize the Absorption, Distribution, Metabolism and Excretion (ADME) of ASA404 After a Single Infusion in Patients With Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01299701. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*